Poster Does Mirtazapine Interfere With Diabetes Treatment?
Main Article Content
Abstract
Objectives: This study aimed to assess any negative effects that treatment with mirtazapine may incur in diabetic patients.
Methods: This study included 33 patients enrolled in naturalistic diabetes treatment that had also been diagnosed withdepression and prescribed mirtazapine for at least 6 months. Another 33 diabetic patients who had not taken any psychiatricmedicines were included as a control group. Body mass index, fasting plasma glucose, HbA1c, total cholesterol, triglyceridelevels, high-density lipoprotein, and low-density lipoprotein were assessed at baseline, 3 months, and 6 months.
Results: The dose of mirtazapine at baseline was 24.3 ± 14.0 mg/d in the mirtazapine group, and the 2 groups did not differin any baseline characteristics except for total cholesterol levels. Body mass index increased in both groups, and the change inthe mirtazapine group (1.0 ± 0.6 kg/m) was significantly greater than that in the control group (0.3 ± 0.4 kg/m, P < 0.001) at6 months. Only the control group exhibited a decrease in fasting plasma glucose, whereas both groups showed a decrease inHbA1c, low-density lipoprotein, and total cholesterol, an increase in high-density lipoprotein, and no change in triglyceridelevels. None of the differences between the groups were statistically significant.
Conclusions: In conclusion, mirtazapine increased the weight gain of diabetic patients; however, other diabetic and lipidmarkers generally did not worsen during the 6-month treatment period. These results suggest that, at least in the short term,mirtazapine is safe for diabetic patients in a stable state and are undergoing appropriate diabetic treatment.
Biography:Duk-In Jon has completed his MD and PhD from Yonsei University, Seoul, Korea. He is the professor of psychiatry in theHallym University Sacred Heart Hospital.
Downloads
Article Details
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).